ReviewNPJ Parkinson's disease2018
Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease.
Review in NPJ Parkinson's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05487885 (Anhedonia, Development, and Emotions), which is not on this map. Cited by 147 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study
Who cites it
147 citing papers in PubMed, 2 syntheses or guidelines pooled it, 268 citations in OpenAlex.
- Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases.Frontiers in neuroscience · 2021Pooled it
- Neuromelanin-Sensitive Magnetic Resonance Imaging in Schizophrenia: A Meta-Analysis of Case-Control Studies.Frontiers in psychiatry · 2021Pooled it
- The swallow tail sign: mechanisms, neuroimaging advances and future perspectives.Insights into imaging · 2026Article
- Nigrostriatal imaging in patients with clinically uncertain Parkinsonian syndromes: a head-to-head comparison between SPECT, PET, and MRI.European journal of nuclear medicine and molecular imaging · 2026Article
- Biological heterogeneity in Parkinson's disease: implications for MRI-based patient stratification.NPJ Parkinson's disease · 2026Review
- Quantitative Assessment of Visible Nigrosome-1 in Patients with Parkinson's Disease.Movement disorders clinical practice · 2026Article
- 7 Tesla MRI with Quantitative Susceptibility Mapping: qualitative grading and quantitative focal measurements of the substantia nigra as a potential biomarker for Parkinson's disease.Neuroradiology · 2026Article
- Comparison of Diagnostic Performance Between Standard Susceptibility Map-Weighted Imaging and Susceptibility Map-Weighted Imaging Reconstructed From Clinical SWI and Neuromelanin MRI in Early Parkinson's Disease.Journal of magnetic resonance imaging : JMRI · 2026Article
- Temperature Dependence of Paramagnetic Species in the Human Brain Tissue: An X-Band EPR Study.Magnetic resonance in medicine · 2026Article
- Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations.Acta pharmaceutica Sinica. B · 2026Review
- Semi-Automated Neuromelanin-Sensitive MRI Reveals Substantia Nigra Volume Reduction in Early Parkinson's Disease with Moderate Diagnostic Performance.Diagnostics (Basel, Switzerland) · 2026Article
- Neuromelanin imaging outperforms free water imaging in diagnosing early Parkinson's disease: a comparative MRI study.NPJ Parkinson's disease · 2026Article
- The Vall d'Hebron Initiative for Parkinson (VHIP) cohort: a prospective, longitudinal, and observational study enrollingFrontiers in aging neuroscience · 2026Article
- Substantia Nigra MRI markers are lower in Alzheimer's disease and are linked to general cognitive function.Brain communications · 2026Article
- The potential of neuromelanin-sensitive MRI in psychiatric disorders.Neuroscience applied · 2026Review
- Neuromelanin, iron and MRI measurements in midbrain tissues of Parkinson's and Alzheimer's subjects.Frontiers in aging neuroscience · 2026Article
- Sex-dependent dopaminergic vulnerability may contribute to sex differences in Parkinson's disease risk.Brain communications · 2026Article
- Melanin and Neuromelanin in Humans: Insights Across Health, Aging, Diseases, and Unexpected Aspects of Fungal Melanogenesis.Biomolecules · 2025Review
- Inverse Association of Locus Coeruleus MRI Integrity With Structural Volume and Its Impact on Individual's Inattentiveness.Human brain mapping · 2025Article
- Neuromelanin-induced cellular stress and neurotoxicity in the pathogenesis of Parkinson's disease.Apoptosis : an international journal on programmed cell death · 2025Review
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of Parkinson's disease (PD) occurs after pathogenesis is advanced and many substantia nigra (SN) dopamine neurons have already died. Now that therapies to block this neuronal loss are under development, it is imperative that the disease be diagnosed at earlier stages and that the response to therapies is monitored. Recent studies suggest this can be accomplished by magnetic resonance imaging (MRI) detection of neuromelanin (NM), the characteristic pigment of SN dopaminergic, and locus coeruleus (LC) noradrenergic neurons. NM is an autophagic product synthesized via oxidation of catecholamines and subsequent reactions, and in the SN and LC it increases linearly during normal aging. In PD, however, the pigment is lost when SN and LC neurons die. As shown nearly 25 years ago by Zecca and colleagues, NM's avid binding of iron provides a paramagnetic source to enable electron and nuclear magnetic resonance detection, and thus a means for safe and noninvasive measure in living human brain. Recent technical improvements now provide a means for MRI to differentiate between PD patients and age-matched healthy controls, and should be able to identify changes in SN NM with age in individuals. We discuss how MRI detects NM and how this approach might be improved. We suggest that MRI of NM can be used to confirm PD diagnosis and monitor disease progression. We recommend that for subjects at risk for PD, and perhaps generally for older people, that MRI sequences performed at regular intervals can provide a pre-clinical means to detect presymptomatic PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.